Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...

(Bloomberg) -- Moderna Inc.’s post-pandemic future was thrown into question Thursday after it disclosed multiple setbacks ...

Just ask Brad Miller, Chief Information Officer (CIO) of Moderna. Brad is passionate about the potential to leverage data, AI, and technology to make a difference in quality and longevity of life.

Moderna, Inc. (NASDAQ:MRNA) investors endured a torrid earnings release that added more pressure on MRNA, as the stock has declined almost 45% from its May 2024 highs. As a result, there's no ...

A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19. Pfizer (PFE) and BioNTech (BNTX) have hit a roadblock in their ...

With analysts estimating that millions of jobs in the STEM fields are currently going unfilled in the U.S., Moderna is doing its part to strengthen the workforce and close that gap. The drugmaker ...

Aleksander Kalka / NurPhoto via Getty Images Moderna lowered its full-year guidance as falling European demand and a difficult U.S. market limited sales of its COVID-19 vaccine. The company ...

Aug 1 (Reuters) - Moderna (MRNA.O), opens new tab on Thursday cut its 2024 sales forecast for COVID-19 and respiratory syncytial virus vaccines by up to 25%, or $1 billion, due partly to low COVID ...

Moderna MRNA has risen 22.1% in the year-to-date period against the industry’s 2.7% fall, as seen in the chart below. The stock also outperformed the sector and the S&P 500. Shares of the ...

Moderna will announce Q2 2024 earnings this Thursday, 1st August. Moderna stock hit highs of $450 per share in late 2021, but has since seen a decrease ~$120, and a current market cap valuation of ...

Moderna Inc.’s stock tumbled 21% Thursday, after the biotech company cut its sales guidance for 2024, offsetting a narrower-than-expected second-quarter loss and revenue that topped estimates.

Moderna MRNA will report second-quarter earnings on Aug 1, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $124.9 million and a loss of $3.47 per share ...